Thrombin-Activatable Fibrinolysis Inhibitor in Breast Cancer Patients

Creative Commons License

Kaftan O., KASAPOĞLU B., Koroglu M., KOŞAR A., Yalcin S.

MEDICAL PRINCIPLES AND PRACTICE, vol.20, no.4, pp.332-335, 2011 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 20 Issue: 4
  • Publication Date: 2011
  • Doi Number: 10.1159/000324547
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.332-335
  • Keywords: Thrombin-activatable fibrinolysis inhibitor, Breast cancer, BLOOD-COAGULATION, RISK, TESTS, TAFI
  • Lokman Hekim University Affiliated: No


Objective: To evaluate the levels of thrombin-activatable fibrinolysis inhibitor (TAFI) activity and also its relationship with other homeostasis markers in breast cancer patients. Subjects and Methods: Forty-two female patients with breast cancer and 24 healthy women (controls) were enrolled in the study and fasting blood samples of all cases were drawn from a large antecubital vein for assay of TAFI and other homeostasis tests. Results: The TAFI levels were 79.5 +/- 15.5 and 39.3 +/- 12.1 in patients and controls, respectively, and the difference was statistically significant (p < 0.001). In the patient group, the serum fibrinogen level was 504.9 +/- 224.8, while in the control group it was 393.9 +/- 100.5, and the difference was also statistically significant (p < 0.001). Conclusion: The data showed that increased levels of TAFI are a contributing factor of thrombotic disorders in breast cancer patients. Copyright (C) 2011 S. Karger AG, Basel